What ChondroFiller does and who it suits

A focal cartilage lesion in the hip does not automatically mean surgery. ChondroFiller® (also marketed as Liquid Cartilage™) is a CE-marked Class III injectable collagen scaffold that can be placed directly into a damaged area of hip cartilage at an outpatient appointment, under ultrasound guidance, without a general anaesthetic or surgical incision.

It is not a steroid or a painkiller. The scaffold works by filling the defect conformally and gelling within minutes to form a stable three-dimensional matrix — a process called acellular matrix-induced chondrogenesis — which recruits the patient's own progenitor cells from the joint lining and subchondral bone, supporting the body's own repair processes. The collagen matrix then gradually degrades as new tissue matures in its place.

The treatment is indicated for focal, full-thickness cartilage defects — typically up to 6 cm² — in adults with otherwise stable hip joints. It is not a treatment for widespread hip osteoarthritis. Published data from Simeonov et al. (Journal of IMAB, 2024), based on 17 patients with a mean age of 31 years, suggest particularly good outcomes for defects smaller than 2 cm² in younger active patients.

For patients weighing whether cartilage preservation is still an option before progressing to hip replacement, ChondroFiller® sits at an important decision point. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment.

How the scaffold works inside the hip joint

The difference between ChondroFiller® and other joint injections lies in what happens after the needle is withdrawn. A hyaluronic acid injection coats the joint surfaces and improves lubrication; a corticosteroid dampens inflammation. Neither repairs the defect itself.

ChondroFiller® is a liquid Type I collagen that transforms within minutes of entering the hip joint, gelling into a firm, porous three-dimensional matrix that conforms precisely to the shape of the lesion — like scaffolding erected inside a gap in a wall. That matrix is not inert: its collagen structure acts as a chemotactic signal, drawing the patient's own progenitor cells inward from the surrounding synovium and the subchondral bone beneath the defect. Once recruited, those cells mature into chondrocytes and begin laying down hyaline-like repair tissue — structurally closer to the original articular surface than the fibrocartilage that forms after microfracture, which offers a weaker and less durable repair.

As new tissue matures, the scaffold is progressively resorbed by the body. MRI MOCART scoring provides an objective window on this process: mean scores progress from approximately 65 at four weeks — reflecting early scaffold integration — to around 82 at one year, indicating ongoing defect filling and bonding with surrounding native cartilage.

Within the hip's deep ball-and-socket joint, delivering the scaffold accurately matters. Ultrasound guidance allows real-time visualisation of needle placement, ensuring the collagen matrix reaches the lesion rather than dispersing into the broader joint space.

The ultrasound-guided injection pathway for the hip

Arriving at the appointment, most patients are surprised by how straightforward the experience is. There is no theatre, no gown change for surgery, and no anaesthetic consent — the procedure takes place on a clinical couch, with the patient lying on their back so the clinician has clear anterior access to the hip joint.

The hip's depth is the central technical challenge. Unlike a more superficial joint, the femoral head sits several centimetres beneath the skin and soft tissue, making freehand needle placement imprecise. Real-time ultrasound resolves this: the clinician tracks the needle continuously on screen as it advances toward the intra-articular space, confirming position before the collagen scaffold is released.

Once injected, ChondroFiller® gels within minutes — and this is the detail most patients find unexpected. Staying reasonably still for a short period immediately after the injection allows the matrix to set firmly at the defect site rather than migrating before it solidifies. The sensation during injection is typically one of mild pressure or fullness deep in the hip, not sharp pain.

Intravenous antibiotic cover is standard to protect the joint during the procedure. Most patients are discharged within the same appointment, usually within an hour of arrival.

What the clinical evidence shows

Hip-specific outcome data, though drawn from smaller series, point consistently in the same direction. In a 2024 study by Simeonov et al. published in the Journal of IMAB, 17 patients with a mean age of 31 years achieved a mean Harris Hip Score improvement of approximately 33 points following ChondroFiller® treatment — a clinically meaningful gain for a young, active cohort.

For broader mechanism context, the manufacturer's April 2025 Clinical Evaluation Report documents approximately 30-point IKDC score improvements in knee patients — well above the established minimal clinically important difference of 16.7 points, and sustained at three-year follow-up in the prospective Jerosch et al. study. These figures reflect knee outcomes, not hip claims; they are cited here because the underlying repair biology is the same scaffold-driven process. MRI MOCART scores of 81–84 at one year confirm solid structural integration of the maturing repair tissue across treated joints.

The safety profile warrants specific attention. The reported complication rate is approximately 0.06%, and the reoperation rate sits at 3–8%. For comparison, microfracture carries a reoperation rate of up to 41%, while ACI and MACI procedures are associated with complication rates of up to 17%. These figures contextualise the risk-benefit balance without implying that surgical routes are never appropriate; for some patients, they remain the right choice.

The honest limitation is that large-scale randomised controlled trial data comparing ChondroFiller® directly with other interventions within the hip joint are not yet available. Current hip evidence rests on smaller case series and technique descriptions, and individual outcomes will depend on defect size, patient age, joint stability, and activity level — all factors that require a formal consultant assessment to weigh properly.

Who is a suitable candidate

Rather than working through a list of contraindications, the more useful starting point is what a hip MRI needs to show before ChondroFiller® becomes a realistic option.

The imaging should confirm a discrete, full-thickness chondral lesion — one that is genuinely focal rather than part of a broader pattern of joint-wide cartilage thinning. Defects below 2 cm² tend to produce the most consistent results; the scaffold can treat lesions up to 6 cm², but the strength of the outcome evidence is greatest for smaller, well-contained defects. Equally important is what the MRI does not show: widespread subchondral damage, severe joint-space narrowing, or significant deformity would generally move the conversation toward a different pathway.

The patients who tend to be appropriate for assessment are those whose overall hip joint health remains manageable despite a defined chondral injury — commonly associated with femoroacetabular impingement or a discrete traumatic event. This includes some patients who have been told they may eventually need a hip replacement but have identifiable focal lesions rather than end-stage arthritis throughout the joint; for this group, a cartilage preservation assessment is a reasonable step before committing to replacement.

Systemic inflammatory arthritis and active infection are absolute contraindications. Joint instability should be addressed before or alongside any scaffold treatment.

Consultant review of existing MRI — or arranging new imaging if none is available — is the practical first step for anyone uncertain about whether their hip meets these criteria.

Recovery: what to expect after the injection

Recovery follows a predictable structure, with the first six weeks being the most significant adjustment. After the injection, partial weight-bearing — typically with crutches — is maintained to allow the collagen scaffold time to stabilise within the defect. Day-to-day planning matters here: work patterns, commuting, and home arrangements all need consideration before the appointment.

From around six weeks, low-impact movement is introduced progressively. Cycling on a stationary bike and swimming are the standard starting points, chosen because they load the hip joint without the peak forces of walking or running on hard ground. Throughout this phase, physiotherapy is a structural part of recovery rather than an optional addition — targeted exercises rebuild the muscle conditioning and hip mechanics that protect the maturing repair tissue as it consolidates.

Return to full sport or high-impact activity is typically expected at around 12 months. This timeline reflects the biology: the scaffold's progressive replacement by hyaline-like cartilage takes many months to mature, and loading the repair site prematurely risks disrupting integration before it is complete.

At one year, a follow-up MRI provides objective evidence of how the repair tissue has settled. Published MOCART data show defect filling progressing from a mean of around 65 at four weeks to over 81 at 12 months — a trajectory that gives both patient and clinician a clear basis for decisions about returning to demanding activity or planning the next stage of hip management.